Open AccessPersonalized approach to the selection of therapy for patients with psoriasisbased on the results of molecular and genetic tests
Author(s) -
L F ZNAMENSKAYA,
Н В Фриго,
С В Ротанов,
И А Волков,
В. А. Волнухин,
М. Б. Жилова
Publication year - 2010
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/vdv961
Subject(s) - infliximab , psoriasis , genotype , locus (genetics) , medicine , dermatology , gene , oncology , genetics , biology , tumor necrosis factor alpha
The article presents the results of tests aimed at revealing biomarkers of patients clinical response to treatment with Infliximaband phototherapy with the use of molecular and genetic technologies. The authors revealed that the predictor of evident clinicalresponse to treatment of psoriasis patients with Infliximab is the homozygous TT genotype at the 676 locus of exon 6 of the TNFR-II gene; predictors of high efficacy and safety of treatment of psoriasis patients with Infliximab with the use of ultraviolet therapy(PUVA and mid-wavelength ultraviolet therapy (311 nm)) are: heterozygous GA genotype at the 19007 locus of the ERCC geneand homozygous CC genotype at the 27945 locus of the XPF gene.